Week‐Long High‐Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double‐Blind, Randomized Clinical Trial

Journal of Interventional Cardiology - Tập 22 Số 4 - Trang 368-377 - 2009
Thùy Anh Nguyễn1, Marie Lordkipanidzé, Jean G. Diodati, Donald Palisaitis, Érick Schampaert, Jacques Turgeon, Chantal Pharand
1Faculties of Pharmacy, Université de Montréal, Montreal, Canada.

Tóm tắt

Background: Adequate platelet inhibition before percutaneous coronary intervention (PCI) reduces periprocedural and long‐term ischemic complications. Reduced response to clopidogrel has been associated with subsequent major adverse cardiovascular events. Strategies to optimize platelet inhibition pre‐PCI are under investigation. This study evaluated the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective PCI in a randomized, prospective, double‐blind, and placebo‐controlled design. Methods: One hundred twenty participants were randomized to one of four groups of clopidogrel: (a) 300 mg on the day prior to angiography; (b) 600 mg on the day prior to angiography; (c) 300 mg followed by 75 mg daily started 1 week prior to angiography; and (d) 300 mg followed by 150 mg daily started 1 week prior to angiography. Platelet aggregation was assessed by light transmission aggregometry (LTA) after stimulation with adenosine diphosphate 20 μM at baseline and at the time of diagnostic coronary angiography. The absolute change in platelet aggregation between these two time points was considered the main outcome measure. Results: At the time of diagnostic coronary angiography, the 300‐mg/150‐mg daily regimen achieved the greatest decrease in platelet aggregation (37 ± 19%), while the 300 mg regimen provided the smallest (20 ± 22%), an absolute difference between the two groups of 17.2 ± 5.1% (P = 0.005). Conclusions: A 300‐mg loading dose of clopidogrel followed by 150 mg daily for 1 week prior to coronary angiography provides more effective platelet inhibition, as defined by LTA, compared to the standard 300‐mg loading dose regimen at the time of coronary intervention.

Từ khóa


Tài liệu tham khảo

10.1016/0735-1097(95)00466-1

10.1016/S0002-9343(96)80077-5

10.1056/NEJMoa010746

10.1001/jama.288.19.2411

10.1016/j.jacc.2005.01.034

10.1002/ccd.10497

10.1161/01.CIR.0000130846.46168.03

10.1093/eurheartj/ehl275

10.1016/j.jacc.2005.12.085

10.1016/j.jacc.2005.01.030

10.1016/j.jacc.2006.06.065

10.1016/j.thromres.2004.07.002

10.1016/j.jacc.2006.06.049

10.1161/01.CIR.0000072771.11429.83

10.1177/0091270009332433

10.1093/eurheartj/ehn417

10.1016/j.jacc.2007.10.002

10.1093/eurheartj/ehi138

10.1016/0735-1097(88)90158-1

10.1093/eurheartj/ehn046

10.1016/j.ehj.2004.07.036

10.1161/CIRCULATIONAHA.106.667741

10.1093/eurheartj/ehl489

Angiolillo DJ, 2008, Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study, Thromb Haemost, 99, 161, 10.1160/TH07-09-0562

10.1016/j.ahj.2006.10.030

10.1097/01.mbc.0000187252.09759.ba

Von Beckerath N, 2005, Absorption, metabolization, and antiplatelet effects of 300‐, 600‐, and 900‐mg loading doses of clopidogrel: Results of the ISAR‐CHOICE (intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088

10.1016/j.jacc.2006.04.090

10.1016/j.thromres.2007.06.012

10.1160/TH04-02-0105

10.1016/j.jacc.2007.01.094

10.1016/j.jacc.2005.10.047

10.1016/j.clpt.2006.07.007

10.1016/j.jacc.2007.12.044

10.1111/j.1538-7836.2005.01751.x

10.1111/j.1538-7836.2007.02655.x

10.1111/j.1538-7836.2007.02656.x

10.1093/eurheartj/ehn419

10.1016/j.amjcard.2006.09.008

Thông tin
Thông tin xuất bản

Journal of Interventional Cardiology

Tập 22 Số 4

368-377

Thông tin tác giả